Clinical pharmacology of the apixaban and frequently asked questions about its clinical use

Abacı, Adnan

Journal Metrics

Impact Factor (2025): 0.6
Scopus: Q3
CiteScore (2023): 1.3
Source Normalized Impact
per Paper:
0.315
SCImago Journal Rank: 0.250

53/4Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and

In titles and abstracts

In keywords

In all

Clinical pharmacology of the apixaban and frequently asked questions about its clinical use [Turk Kardiyol Dern Ars]

Turk Kardiyol Dern Ars. 2016; 44(2): 1-6

Clinical pharmacology of the apixaban and frequently asked questions about its clinical use

Adnan Abacı
Gazi Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara

Apixaban is a new, strong, reversible, competitive direct inhibitor of factor Xa. By inhibiting factor Xa, it prevents the conversion of prothrombin to thrombin. Large, randomized clinical trials showed that apixaban is superior to varfarin in the prevention of stroke in atrial fibrillation and caused less bleeding than varfarin. This article summarized clinical pharmacology of the apixaban and responded to frequently asked questions about it.

Keywords: Apixaban, reversible, competitive.

Corresponding Author: Adnan Abacı, Türkiye
Manuscript Language: Turkish

CITE

Full Text PDF Download citation RIS EndNote BibTex Medlars Procite Reference Manager Send email to author Similar articles PubMed Google Scholar